- Conditions
- Angioedema, Hereditary, Types I and II
- Interventions
- KVD824, Placebo to KVD824
- Drug
- Lead sponsor
- KalVista Pharmaceuticals, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hereditary Angioedema
- Interventions
- STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Hypertension, Diabetes Type 2
- Interventions
- Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
- Conditions
- Hereditary Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
- Conditions
- Kidney Transplant
- Interventions
- Berinert, Placebo for Berinert
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Deucrictibant
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule
- Drug
- Lead sponsor
- Institute for Asthma and Allergy
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Wheaton, Maryland
- Conditions
- Angioedema
- Interventions
- Placebo, Lanadelumab
- Other · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- C1 esterase inhibitor [human] liquid, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- C1-esterase inhibitor
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
- Conditions
- Hereditary Angioedema
- Interventions
- CSL312
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more
- Conditions
- ACE Inhibitor-associated Angioedema
- Interventions
- icatibant, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • Nashville, Tennessee
- Conditions
- Hereditary Angioedema
- Interventions
- Navenibart
- Drug
- Lead sponsor
- Astria Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
- Conditions
- Hereditary Angioedemas
- Interventions
- No intervention
- Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Miami, Florida • Saint Charles, Illinois + 4 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab 300 mg
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II, HAE With Normal C1 Esterase Inhibitor
- Interventions
- deucrictibant
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more